Advertisement
Advertisement
SXTP
60 Degrees Pharmaceuticals, Inc. Common Stock
1.12
USDSponsored
-0.03
-2.61%
Aug 07, 15:56 UTC -4
Closed
After-Market
1.17
+0.05
+4.46%
SXTP Earnings Reports
Positive Surprise Ratio
SXTP beat 2 of 11 last estimates.
18%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
60 Degrees Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On May 15, 2026, SXTP reported earnings of -1.28 USD per share (EPS) for Q1 26, missing the estimate of -0.77 USD, resulting in a -65.12% surprise. Revenue reached 162.09 thousand, compared to an expected 443.70 thousand, with a -63.47% difference. The market reacted with a -4.79% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Relay Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.41
Surprise
-2.78%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Profound Medical Corp. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
$0.26
Surprise
+199.01%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
FAQ
What were 60 Degrees Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, 60 Degrees Pharmaceuticals, Inc. Common Stock reported EPS of -$1.28, missing estimates by -65.12%, and revenue of $162.09K, -63.47% below expectations.
How did the market react to 60 Degrees Pharmaceuticals, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -4.79%, changed from $1.46 before the earnings release to $1.39 the day after.
When is 60 Degrees Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for 60 Degrees Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on --
analysts, 60 Degrees Pharmaceuticals, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement